---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-023968"
form_type: "8-K"
ticker: "CODX"
cik: "0001692415"
company_name: "Co-Diagnostics, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:16:19.026072+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Co-Diagnostics Q2 revenue falls to $0.2M from $2.7M; net loss $7.7M

## Summary
- Revenue $0.2M vs $2.7M in Q2 2024; no grant revenue recognized in Q2 2025.
- Operating loss $8.1M vs $7.7M prior year; expenses down 19.1% to $8.2M.
- Net loss $7.7M ($0.23 per share) vs $7.6M ($0.25 per share) in Q2 2024.
- Cash & marketable securities $13.4M as of June 30, 2025; adjusted EBITDA loss $7.2M.
- On track to initiate clinical evaluations for Co-Dx PCR platform tests before year-end; enhanced COVID-19 test trial starting imminently.

## SEC filing metadata
- accession: 0001641172-25-023968
- form_type: 8-K
- ticker: CODX
- cik: 0001692415
- company_name: Co-Diagnostics, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1692415/000164117225023968/0001641172-25-023968-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1692415/000164117225023968/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-023968
- JSON: https://secwatch.observer/filing/0001641172-25-023968.json
- Plain text: https://secwatch.observer/filing/0001641172-25-023968.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.